Verhoeven, Jeroen G. H. P. http://orcid.org/0000-0002-5860-3782
Baan, Carla C.
Peeters, Annemiek M. A.
Clahsen-van Groningen, Marian C.
Nieboer, Daan
Herzog, Mariëlle
Eccleston, Marc
Hesselink, Dennis A.
Boer, Karin
Funding for this research was provided by:
Nierstichting (No. 17OI03)
Article History
Received: 19 May 2020
Accepted: 4 November 2020
First Online: 11 February 2021
Ethics approval and consent to participate
: The study was approved by the Medical Ethical Committee of the Erasmus MC, University Medical Center Rotterdam (MERB number METC-2012-421). All participants provided written informed consent prior to enrolment. The study was conducted according to the guidelines of the Helsinki Declaration. No potentially identifiable human images or data is presented in this study.
: CCFN concentrations or values were measured and (partly) subsidized by the manufacturer (NuQ® ELISA (Belgian Volition SPRL, Isnes, Belgium)). D.A. Hesselink has received lecture and consulting fees from Astellas Pharma, Chiesi Farmaceutici SpA and Novartis Pharma, as well as grant support from Astellas Pharma, Chiesi Farmaceutici SpA (paid to his institution). Mariëlle Herzog and Marc Eccleston are employed by Belgian Volition SA, Belgium.